loading
Precedente Chiudi:
$1.32
Aprire:
$1.32
Volume 24 ore:
35,680
Relative Volume:
0.12
Capitalizzazione di mercato:
$56.19M
Reddito:
$51.13M
Utile/perdita netta:
$-93.80M
Rapporto P/E:
-0.5919
EPS:
-2.23
Flusso di cassa netto:
$-129.10M
1 W Prestazione:
-1.49%
1M Prestazione:
+3.13%
6M Prestazione:
-53.02%
1 anno Prestazione:
-57.42%
Intervallo 1D:
Value
$1.31
$1.33
Intervallo di 1 settimana:
Value
$1.29
$1.39
Portata 52W:
Value
$0.89
$4.29

Repare Therapeutics Inc Stock (RPTX) Company Profile

Name
Nome
Repare Therapeutics Inc
Name
Telefono
(857) 412-7018
Name
Indirizzo
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Name
Dipendente
129
Name
Cinguettio
@reparerx
Name
Prossima data di guadagno
2023-08-09
Name
Ultimi documenti SEC
Name
RPTX's Discussions on Twitter

Confronta RPTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RPTX
Repare Therapeutics Inc
1.31 57.05M 51.13M -93.80M -129.10M -2.23
Biotechnology icon
ONC
Beigene Ltd Adr
241.85 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.88 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.31 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
590.43 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.83 5.92B 0 -153.72M -103.81M -2.00

Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-06-09 Aggiornamento Stifel Hold → Buy
2023-02-03 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-01-06 Iniziato CapitalOne Overweight
2022-04-12 Downgrade Stifel Buy → Hold
2022-03-17 Ripresa Goldman Buy
2021-09-23 Iniziato Stifel Buy
2021-09-13 Iniziato H.C. Wainwright Buy
2021-06-28 Iniziato Guggenheim Buy
2021-03-01 Iniziato Berenberg Buy
2020-10-28 Iniziato Northland Capital Outperform
2020-07-14 Iniziato Cowen Outperform
2020-07-14 Iniziato Goldman Neutral
2020-07-14 Iniziato Morgan Stanley Overweight
2020-07-14 Iniziato Piper Sandler Overweight
Mostra tutto

Repare Therapeutics Inc Borsa (RPTX) Ultime notizie

pulisher
May 19, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) is MPM Asset Management LLC's 6th Largest Position - MarketBeat

May 19, 2025
pulisher
May 19, 2025

MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat

May 19, 2025
pulisher
May 16, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World

May 16, 2025
pulisher
May 14, 2025

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News

May 14, 2025
pulisher
May 14, 2025

RPTX Advances Pipeline with Strategic Partnership | RPTX Stock N - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tower Research Capital LLC TRC Purchases 23,127 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 14, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business - citybiz

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - ADVFN

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Re - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates - TipRanks

May 13, 2025
pulisher
May 07, 2025

Repare Therapeutics Inc’s Market Journey: Closing Weak at 1.33, Down -5.00 - DWinneX

May 07, 2025
pulisher
May 07, 2025

Marshall Wace LLP Decreases Stake in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

JPMorgan Chase & Co. Boosts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 06, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Has $455,000 Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 04, 2025
pulisher
May 02, 2025

Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo

May 02, 2025
pulisher
May 01, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

May 01, 2025
pulisher
May 01, 2025

Repare Therapeutics Inc. Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News

May 01, 2025
pulisher
May 01, 2025

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace

May 01, 2025
pulisher
Apr 29, 2025

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Apr 29, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat

Apr 25, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News

Apr 25, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Repare Therapeutics Inc (RPTX) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Apr 23, 2025
pulisher
Apr 21, 2025

B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 16, 2025

Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics - Investing.com UK

Apr 16, 2025
pulisher
Apr 12, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock By Investing.com - Investing.com India

Apr 12, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock - Investing.com

Apr 11, 2025
pulisher
Apr 04, 2025

Repare Therapeutics Stock Hits 52-Week Low at $0.98 Amid Market Challenges - Investing.com

Apr 04, 2025
pulisher
Apr 03, 2025

Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals

Apr 03, 2025
pulisher
Apr 01, 2025

Repare Therapeutics details discovery of PLK4 inhibitor RP-1664 - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Appoints Steve Forte CEO - citybiz

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics appoints CFO as new CEO - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Names Forte as President, CEO - MarketWatch

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Announces Leadership Transitions - Business Wire

Mar 31, 2025

Repare Therapeutics Inc Azioni (RPTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.89
price down icon 0.52%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Capitalizzazione:     |  Volume (24 ore):